Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Aadi Bioscience, a biopharmaceutical company focused on precision therapies for genetically-defined cancers, will participate in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. Founder and CEO Neil Desai and the executive team will present virtually on May 24, starting at 7:00 AM EDT. Aadi recently received FDA approval for its drug FYARRO for treating advanced malignant PEComa and has launched it commercially. The company has also initiated the PRECISION 1 trial for solid tumors with specific genetic alterations.

LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., and senior members of Aadi’s executive team will participate virtually in the H.C. Wainwright Global Investment Conference, to be held in person and virtually May 23-26, 2022 in Miami, FL.

H.C. Wainwright Global Investment Conference
Format: Pre-recorded presentation and 1x1 Meetings
Date: Tuesday, May 24^th, 2022
Time: Recording available beginning 7:00 AM EDT
Webcast Link: Click Here

The recorded presentation will also be available for 90 days on Aadi’s website within the News/Events & Presentations section.

About Aadi Bioscience  
Aadi is a biopharmaceutical company focused on precision therapies for genetically-defined cancers. Aadi’s primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. In November 2021, Aadi received FDA approval for FYARRO™ for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa), and in February 2022 Aadi announced the commercial launch of FYARRO in this indication.  

Based on data from Aadi’s Phase 2 registrational study (the Advanced Malignant PEComa Trial or “AMPECT”) with FYARRO, and, following discussions with the FDA about other emerging data with FYARRO, Aadi has initiated PRECISION 1, a Phase 2 tumor-agnostic registrational trial in mTOR inhibitor-naïve solid tumors harboring TSC1 or TSC2 inactivating alterations. More information on Aadi’s development pipeline is available on the Aadi website at www.aadibio.com. 

Contacts

Investors:
Irina Koffler
LifeSci Advisors LLC
ikoffler@lifesciadvisors.com

Media:
Darren Opland, Ph.D.
LifeSci Communications
darren@lifescicomms.com

FAQ

What is Aadi Bioscience participating in on May 24, 2022?

Aadi Bioscience will present virtually at the H.C. Wainwright Global Investment Conference on May 24, 2022.

What time will Aadi's presentation be available on May 24, 2022?

The presentation will be available starting at 7:00 AM EDT on May 24, 2022.

What is FYARRO and what indication does it treat?

FYARRO is a drug approved by the FDA for treating adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

What is the PRECISION 1 trial by Aadi Bioscience?

The PRECISION 1 trial is a Phase 2 tumor-agnostic registrational trial for mTOR inhibitor-naïve solid tumors with TSC1 or TSC2 inactivating alterations.

Where can I find more information about Aadi Bioscience's development pipeline?

More information about Aadi's development pipeline is available on their website at www.aadibio.com.